Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report) CEO Jitendra Mohan sold 171,064 shares of Astera Labs stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $103.53, for a total transaction of $17,710,255.92. Following the sale, the chief executive officer now owns 628,895 shares in the company, valued at approximately $65,109,499.35. This represents a 21.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jitendra Mohan also recently made the following trade(s):
- On Monday, November 25th, Jitendra Mohan sold 173,366 shares of Astera Labs stock. The shares were sold at an average price of $110.12, for a total transaction of $19,091,063.92.
- On Friday, October 11th, Jitendra Mohan sold 47,667 shares of Astera Labs stock. The stock was sold at an average price of $70.26, for a total transaction of $3,349,083.42.
Astera Labs Stock Performance
NASDAQ:ALAB opened at $99.60 on Thursday. Astera Labs, Inc. has a 12 month low of $36.22 and a 12 month high of $113.85. The firm has a fifty day simple moving average of $73.12 and a two-hundred day simple moving average of $60.57.
Hedge Funds Weigh In On Astera Labs
Institutional investors have recently modified their holdings of the company. Fred Alger Management LLC grew its position in Astera Labs by 1,361.0% in the 3rd quarter. Fred Alger Management LLC now owns 2,821,921 shares of the company’s stock valued at $147,840,000 after purchasing an additional 2,628,765 shares during the period. Vanguard Group Inc. acquired a new position in shares of Astera Labs during the first quarter valued at about $127,268,000. Westfield Capital Management Co. LP bought a new stake in shares of Astera Labs during the third quarter worth about $52,049,000. The Manufacturers Life Insurance Company raised its holdings in shares of Astera Labs by 15,477.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 879,055 shares of the company’s stock worth $46,054,000 after acquiring an additional 873,412 shares during the last quarter. Finally, Spyglass Capital Management LLC bought a new position in Astera Labs in the 3rd quarter valued at about $38,565,000.
Wall Street Analysts Forecast Growth
ALAB has been the topic of several recent research reports. Barclays lifted their target price on Astera Labs from $70.00 to $87.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Citigroup started coverage on Astera Labs in a research note on Monday, November 18th. They issued a “buy” rating and a $120.00 price objective on the stock. Deutsche Bank Aktiengesellschaft increased their target price on shares of Astera Labs from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Evercore ISI dropped their price target on shares of Astera Labs from $98.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Morgan Stanley upped their price objective on shares of Astera Labs from $74.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $94.67.
View Our Latest Analysis on Astera Labs
About Astera Labs
Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.
Recommended Stories
- Five stocks we like better than Astera Labs
- Want to Profit on the Downtrend? Downtrends, Explained.
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Investing In Automotive Stocks
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Investors Need to Know About Upcoming IPOs
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.